Healthcare >> CEO Interviews >> December 18, 2000
JAMES A. COUR has been President and Chief Executive Officer of
Cytomedix, Inc. since April 2000. Before joining the company, Mr. Cour
served for 19 years with Baxter International Inc. in a variety of
management positions, most recently as Vice President of Portfolio
Strategy. In this capacity Mr. Cour developed a detailed knowledge of
many of the new and cutting-edge medical technologies emerging from the
US and international health care markets. He is thus particularly well-
suited to formulate and direct the company's emerging business strategy.
From 1994 to 1996 Mr. Cour served in Japan as General Manager of
Operations for Baxter Limited, Baxter's $725 million Japanese operating
subsidiary. There he successfully implemented a complex restructuring of
the subsidiary's operations, resulting in significant savings and
important improvements in customer service levels. Mr. Cour also served
as Director of Business Development for Baxter's Global Business Group
where he gained in-depth knowledge of the international health care
market. He has a Master of Business Administration Degree, with a
specialization in Finance, from the University of Chicago Graduate
School of Business and a Bachelor of Business Administration Degree,
with honors in Accountancy, from the University of Notre Dame. He passed
the Uniform Certified Public Accounting Examination and has been
admitted to practice as a CPA in the State of Illinois. Profile
Cytomedix?
Mr. Cour: Cytomedix is a biotechnology company, focusing on development
of cellular therapies for the treatment of
